Product Details

Trelegy Ellipta

Fluticasone Furoate + Umeclidinium Bromide + Vilanterol Trifenatate
100 mcg + 62.5 mcg + 25 mcg
Powder for Inhalation
30-Dose Pack

DIN/PIN/NPN

02474522

Manufacturer

GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care

Formulary Listing Date

2019-09-30  

Unit Price

137.6700

Amount MOH Pays

137.6700

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

Trelegy Ellipta: Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.

ATC Code

R03AL08

Interchangeable Products

NO  

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
567 Indefinite

For the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA).
 

EAP Criteria

NO

Product Monograph

View Monograph